Ptc Therapeutics, Inc.
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
Bought 1.25M
Bought 666.7K · Sold 66.7K
Bought 333.3K
Granted 129.0K · Bought 632.6K · Sold 27.5K
Granted 519.3K · Sold 128.6K
Granted 1.60M · Sold 1.59M
Granted 807.9K · Sold 749.1K
Granted 130.0K · Sold 114.5K
Granted 242.7K · Sold 194.2K
Granted 90.6K · Bought 7.7K · Sold 12.3K
Granted 61.4K · Sold 23.5K
Granted 270.4K · Sold 212.6K
Granted 657.7K · Sold 647.4K
Granted 99.2K · Bought 27.0K · Sold 85.0K
Granted 57.9K · Sold 68.7K
Granted 81.2K · Sold 49.9K
Granted 108.0K · Sold 84.1K
Granted 6.5K · Bought 25.0K · Sold 2.5K
Granted 100.5K · Sold 91.2K
Granted 66.5K · Sold 44.0K
Granted 34.5K · Sold 12.0K
Granted 21.8K
Granted 133.5K · Sold 150.1K
Granted 32.7K · Sold 11.7K
Bought 20.0K
Granted 102.5K · Sold 91.8K
Granted 10.3K
Granted 37.7K · Sold 31.1K
Granted 7.3K
Granted 6.0K
Sold 2.2K
Sold 3.7K
Granted 7.0K · Bought 766.7K · Sold 7.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Koppel AdamDirector · 2 transactions | — | 3.42Mas of Jun 2013 | — | 1.25M | — |
| Credit Suisse Ag/Former 10% Owner · 2 transactions | — | 2.53Mas of Jun 2013 | — | — | — |
| HBM Healthcare Investments (Cayman) Ltd.10% owner · 4 transactions | — | 2.44Mas of Dec 2013 | — | 666.7K | 66.7K |
| Allen Paul G +6 co-filersDirector · 5 transactions | — | 1.70Mas of Jun 2013 | — | 333.3K | — |
| Schmertzler MichaelDirector · 31 transactions | — | 1.52M | 129.0K | 632.6K | 27.5K |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director · 54 transactions | — | 394.0K | 519.3K | — | 128.6K |
| Peltz Stuart WalterCHIEF EXECUTIVE OFFICER, Director · 193 transactions | — | 381.1Kas of Jan 2023 | 1.60M | — | 1.59M |
| Boulding Mark ElliottEXEC. VP AND CLO · 249 transactions | — | 107.1K | 807.9K | — | 749.1K |
| Souza MarcioChief Operating Officer · 26 transactions | — | 102.4Kas of Feb 2020 | 130.0K | — | 114.5K |
| Pauwels EricCHIEF BUSINESS OFFICER · 96 transactions | — | 91.0K | 242.7K | — | 194.2K |
| Gravier PierreCHIEF FINANCIAL OFFICER · 12 transactions | — | 87.3K | 90.6K | 7.7K | 12.3K |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · 19 transactions | — | 79.1K | 61.4K | — | 23.5K |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · 128 transactions | — | 70.2K | 270.4K | — | 212.6K |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · 209 transactions | — | 62.9K | 657.7K | — | 647.4K |
| Rothera MarkChief Commercial Officer · 48 transactions | — | 43.0Kas of May 2017 | 99.2K | 27.0K | 85.0K |
| Hirawat Claudia de Oliveira RibeiroPresident · 25 transactions | — | 39.4Kas of Jan 2015 | 57.9K | — | 68.7K |
| Hill Emily LuisaCHIEF FINANCIAL OFFICER · 32 transactions | — | 38.9Kas of Mar 2023 | 81.2K | — | 49.9K |
| Kovacs Shane William CharlesChief Financial Officer · 8 transactions | — | 37.9Kas of May 2017 | 108.0K | — | 84.1K |
| Svoronos DawnDirector · 9 transactions | — | 29.0Kas of Jun 2022 | 6.5K | 25.0K | 2.5K |
| Southwell David PDirector · 32 transactions | — | 22.5K | 100.5K | — | 91.2K |
| Zeldis Jerome BDirector · 16 transactions | — | 22.5K | 66.5K | — | 44.0K |
| Steele Glenn Jr MD PHDDirector · 9 transactions | — | 22.5K | 34.5K | — | 12.0K |
| Smith Mary L.Director · 7 transactions | — | 21.8K | 21.8K | — | — |
| Jacobson Allan StevenDirector · 48 transactions | — | 21.5K | 133.5K | — | 150.1K |
| Young AlethiaDirector · 10 transactions | — | 21.1K | 32.7K | — | 11.7K |
| Bolte AxelDirector · 1 transaction | — | 20.0Kas of Jun 2013 | — | 20.0K | — |
| Reeve EmmaDirector · 55 transactions | — | 10.7K | 102.5K | — | 91.8K |
| Bell William F. Jr.Director · 3 transactions | — | 10.3Kas of Feb 2024 | 10.3K | — | — |
| Okey StephanieDirector · 17 transactions | — | 8.0K | 37.7K | — | 31.1K |
| Chutter Jessica CarolineDirector · 2 transactions | — | 7.3K | 7.3K | — | — |
| Ong TuyenChief Medical Officer · 1 transaction | — | 6.0Kas of Jan 2017 | 6.0K | — | — |
| Spiegel Robert J.Chief Medical Officer · 3 transactions | — | 3.2Kas of Mar 2015 | — | — | 2.2K |
| Kranda Michael LDirector · 3 transactions | — | 2.2Kas of Mar 2015 | — | — | 3.7K |
| Aldrich RichardDirector · 6 transactions | — | 104as of Jun 2015 | 7.0K | 766.7K | 7.0K |
| Complete Pharma Holdings II, LLC10% owner · 1 transaction | — | 0as of Apr 2017 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -774.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.